D.E. Shaw & Co
ZVRA icon

D.E. Shaw & Co’s Zevra Therapeutics ZVRA Stock Holding History

D.E. Shaw & Co’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.89M Sell
846,457
-17,289
-2% -$156K ﹤0.01% 1821
2025
Q4 		$7.74M Buy
863,746
+137,916
+19% +$1.3M ﹤0.01% 1968
2025
Q3 		$6.9M Buy
725,830
+536,517
+283% +$5.38M ﹤0.01% 1954
2025
Q2 		$1.67M Buy
189,313
+161,943
+592% +$1.31M ﹤0.01% 2873
2025
Q1 		$205K Buy
27,370
+2,295
+9% +$18.2K ﹤0.01% 3924
2024
Q4 		$209K Buy
+25,075
New +$214K ﹤0.01% 4065
2022
Q2 		– Sell
-10,453
Closed -$53K – 5840
2022
Q1 		$53K Sell
10,453
-13,356
-56% -$85K ﹤0.01% 5132
2021
Q4 		$207K Buy
+23,809
New +$212K ﹤0.01% 4867

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

D.E. Shaw & Co's ZVRA Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Zevra Therapeutics (ZVRA) stake by 2% in Q1 2026, selling an estimated $156K and leaving 846,457 shares worth $7.89M. The position accounts for ﹤0.01% of the portfolio, ranked #1821.

D.E. Shaw & Co first reported a position in ZVRA in Q4 2021 and has held it in 8 quarters since. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • D.E. Shaw & Co held 846,457 shares of Zevra Therapeutics worth $7.89M as of Q1 2026.
  • D.E. Shaw & Co sold 17,289 Zevra Therapeutics shares in Q1 2026, an estimated $156K.
  • Zevra Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1821 holding.
  • D.E. Shaw & Co first reported a position in Zevra Therapeutics in Q4 2021 and has held it in 8 quarters since.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.